Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | SVP Drug Discovery & Early Dev | August 31, 2017 | September 01, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date August 31, 2017 · Filed September 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,441 |
Ending reported balance
After 2017-08-31 transaction · row 30
30 source rows · reconciled sequenceRow 1 · 2017-08-31 · Exercise / conversion · Acquired 16,666 · Balance 63,107 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 2 · 2017-08-31 · Sale · Disposed 16,666 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 3 · 2017-08-31 · Exercise / conversion · Acquired 15,206 · Balance 61,647 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 4 · 2017-08-31 · Sale · Disposed 15,206 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 5 · 2017-08-31 · Exercise / conversion · Acquired 2,294 · Balance 48,735 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 6 · 2017-08-31 · Sale · Disposed 2,294 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 7 · 2017-08-31 · Exercise / conversion · Acquired 11,552 · Balance 57,993 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 8 · 2017-08-31 · Sale · Disposed 11,552 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 9 · 2017-08-31 · Exercise / conversion · Acquired 13,448 · Balance 59,889 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 10 · 2017-08-31 · Sale · Disposed 13,448 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 11 · 2017-08-31 · Exercise / conversion · Acquired 3,795 · Balance 50,236 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 12 · 2017-08-31 · Sale · Disposed 3,795 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 13 · 2017-08-31 · Exercise / conversion · Acquired 21,204 · Balance 67,645 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 14 · 2017-08-31 · Sale · Disposed 21,204 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 15 · 2017-08-31 · Exercise / conversion · Acquired 1,079 · Balance 47,520 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 16 · 2017-08-31 · Sale · Disposed 1,079 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 17 · 2017-08-31 · Exercise / conversion · Acquired 13,920 · Balance 60,361 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 18 · 2017-08-31 · Sale · Disposed 13,920 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 19 · 2017-08-31 · Exercise / conversion · Acquired 617 · Balance 47,058 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 20 · 2017-08-31 · Sale · Disposed 617 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 21 · 2017-08-31 · Exercise / conversion · Acquired 11,883 · Balance 58,324 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 22 · 2017-08-31 · Sale · Disposed 11,883 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 23 · 2017-08-31 · Exercise / conversion · Acquired 694 · Balance 47,135 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 24 · 2017-08-31 · Sale · Disposed 694 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 25 · 2017-08-31 · Exercise / conversion · Acquired 2,639 · Balance 49,080 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 26 · 2017-08-31 · Sale · Disposed 2,639 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 27 · 2017-08-31 · Exercise / conversion · Acquired 695 · Balance 47,136 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 28 · 2017-08-31 · Sale · Disposed 695 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 29 · 2017-08-31 · Exercise / conversion · Acquired 2,638 · Balance 49,079 F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Row 30 · 2017-08-31 · Sale · Disposed 2,638 · Balance 46,441 F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-03-05 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · 2017-08-31 · Exercise / conversion · Disposed 21,204 · Balance 0 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2022-03-05 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 32
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 32 · 2017-08-31 · Exercise / conversion · Disposed 13,920 · Balance 0 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.96 · Expires 2025-02-26 | Direct | 8,750 |
Reported balance
After 2017-08-31 transaction · row 33
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 33 · 2017-08-31 · Exercise / conversion · Disposed 2,294 · Balance 8,750 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2021-02-28 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 34
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 34 · 2017-08-31 · Exercise / conversion · Disposed 11,883 · Balance 0 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.65 · Expires 2024-02-24 | Direct | 5,000 |
Reported balance
After 2017-08-31 transaction · row 35
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 35 · 2017-08-31 · Exercise / conversion · Disposed 13,448 · Balance 5,000 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.10 · Expires 2019-02-26 | Direct | 2,638 |
Reported balance
After 2017-08-31 transaction · row 36
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 36 · 2017-08-31 · Exercise / conversion · Disposed 2,639 · Balance 2,638 |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.10 · Expires 2019-02-26 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 37
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 37 · 2017-08-31 · Exercise / conversion · Disposed 2,638 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-03-05 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 38
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 38 · 2017-08-31 · Exercise / conversion · Disposed 3,795 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2022-03-05 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 39
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 39 · 2017-08-31 · Exercise / conversion · Disposed 1,079 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.67 · Expires 2026-02-23 | Direct | 14,517 |
Reported balance
After 2017-08-31 transaction · row 40
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 40 · 2017-08-31 · Exercise / conversion · Disposed 16,666 · Balance 14,517 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.96 · Expires 2025-02-26 | Direct | 3,750 |
Reported balance
After 2017-08-31 transaction · row 41
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 41 · 2017-08-31 · Exercise / conversion · Disposed 15,206 · Balance 3,750 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2021-02-28 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 42
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 42 · 2017-08-31 · Exercise / conversion · Disposed 617 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.65 · Expires 2024-02-24 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 43
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 43 · 2017-08-31 · Exercise / conversion · Disposed 11,552 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.10 · Expires 2019-02-26 | Direct | 695 |
Reported balance
After 2017-08-31 transaction · row 44
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 44 · 2017-08-31 · Exercise / conversion · Disposed 694 · Balance 695 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.10 · Expires 2019-02-26 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 45
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 45 · 2017-08-31 · Exercise / conversion · Disposed 695 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017.
F2: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 695 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 45 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 695 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 694 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 44 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695 Underlying: Common Stock · 694 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,552 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 43 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,552 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 617 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 42 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 617 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,206 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 41 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 15,206 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,666 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 40 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,517 Underlying: Common Stock · 16,666 shares Expires 2026-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,079 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 39 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,079 shares Expires 2022-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,795 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 38 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,795 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,638 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 37 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,638 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,639 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 36 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638 Underlying: Common Stock · 2,639 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 13,448 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 35 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 13,448 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,883 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 34 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,883 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,294 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 33 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 2,294 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 13,920 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 32 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,920 shares Expires 2022-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 21,204 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · derivative · entry 31 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,204 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,638 | $15.00 | $39,570.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 30 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,638 | $11.10 | $29,281.80 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 29 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 695 | $15.00 | $10,425.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 28 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 695 | $11.10 | $7,714.50 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 27 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,639 | $15.00 | $39,585.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 26 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,639 | $11.10 | $29,292.90 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 25 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 694 | $15.00 | $10,410.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 24 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 694 | $11.10 | $7,703.40 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 23 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,883 | $15.00 | $178,245.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 22 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,883 | $9.42 | $111,937.86 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 21 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 617 | $15.00 | $9,255.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 20 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 617 | $9.42 | $5,812.14 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 19 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,058 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 13,920 | $15.00 | $208,800.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 18 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 13,920 | $6.30 | $87,696.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 17 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,079 | $15.00 | $16,185.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 16 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,079 | $6.30 | $6,797.70 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 15 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 21,204 | $15.00 | $318,060.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 14 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 21,204 | $6.00 | $127,224.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 13 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,795 | $15.00 | $56,925.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 12 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,795 | $6.00 | $22,770.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 11 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 13,448 | $15.00 | $201,720.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 10 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 13,448 | $9.65 | $129,773.20 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 9 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,552 | $15.00 | $173,280.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 8 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,552 | $9.65 | $111,476.80 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 7 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,294 | $15.00 | $34,410.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 6 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,294 | $7.96 | $18,260.24 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 5 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,206 | $15.00 | $228,090.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 4 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,206 | $7.96 | $121,039.76 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 3 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 16,666 | $15.00 | $249,990.00 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 2 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 23:20 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 16,666 | $6.67 | $111,162.22 |
DisclosureSEC source: 0001061983-17-000052 · edgardoc.xml · nonDerivative · entry 1 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,537 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · derivative · entry 5 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,537 Underlying: Common Stock · 13,537 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 6,463 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · derivative · entry 4 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,463 Underlying: Common Stock · 6,463 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 20,000 | $0.00 | $20.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · nonDerivative · entry 3 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,194 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 5,986 | $10.60 | $63,451.60 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · nonDerivative · entry 2 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,194 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 15,000 | $0.00 | $15.00 |
DisclosureSEC source: 0001061983-17-000017 · edgardoc.xml · nonDerivative · entry 1 Morgan Bradley Paul · CIK 0001659025 · SVP Drug Discovery & Early Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,180 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.